See More StocksHome

NCT

Intercont (Cayman) Limited Ordinary shares

Show Trading View Graph

Mentions (24Hr)

1

0.00% Today

Reddit Posts

β€’r/pennystocksβ€’See Post

Could be a good upside if flips

β€’r/smallstreetbetsβ€’See Post

Did NCT’s shareholder statement actually clear anything up?

β€’r/WallStreetbetsELITEβ€’See Post

$CRDL Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

β€’r/wallstreetbetsβ€’See Post

Imorgon going 80% of all my money in on Moderna

Mentions

NCT?

Mentions:#NCT
β€’r/stocksSee Comment

Oral obesity assets in development: naperiglipron (LY3549492): NCT07232732: Phase 1, Obesity NCT06683508: Phase 2, Obesity "Oral GGG" (LY4086940): NCT06945419: Phase 1, Obesity +/- T2D NCT07890376: Phase 2, Obesity

Mentions:#NCT#GGG

That information is already openly available through [clinicaltrials.gov](http://clinicaltrials.gov) \- 267 enrolled, which means \~16-17 extra people lived in the experimental arm assuming an equalish split [https://clinicaltrials.gov/study/NCT03897881?rank=1](https://clinicaltrials.gov/study/NCT03897881?rank=1)

Mentions:#NCT

It's still going to be a case by case basis, but that doesn't mean the techniques and general ideas can't generalize. There's already a bunch of similar trials running: * Lung (NSCLC), adjuvant β€” INTerpath-002, Phase 3 * Lung (NSCLC), post-neoadjuvant β€” INTerpath-009, Phase 3 * Lung (NSCLC), stage I β€” INTerpath-014, Phase 3 * Lung (squamous), metastatic β€” INTerpath-013, Phase 2 * Kidney, adjuvant β€” INTerpath-004, Phase 2 * Bladder, muscle-invasive β€” INTerpath-005, Phase 1/2 * Bladder, non-muscle-invasive β€” NCT06833073, Phase 2 * Melanoma, metastatic β€” INTerpath-012, Phase 2 * Pancreatic, adjuvant β€” IMcode003, Phase 2 * Head & neck, adjuvant β€” TG4050.02, Phase 1/2 * Liver (HCC) β€” GNOS-PV02, Phase 2 * Melanoma, metastatic β€” EVX-01, Phase 2 Some of those will may turn out better than others, but overall progress could still be massive.

β€’r/stocksSee Comment

EloraTZP suite of studies: Eloralintide +/- tirzepatide (NCT06603571): Phase 2, Obesity in T2D, Primary Completion 6-2026

Mentions:#NCT

NCT πŸ‘€

Mentions:#NCT

I think it's mostly about it being at $1.2B which is very high for a company with no revenue, so that means investors are counting on a high chance for it to be successful. Obviously if everything goes great it'll be worth more, but the current price is discounted based on the risk that things don't go well. Here's it's analysis: **TL;DR:** I checked each claim against Alpha Tau's filings, press releases, and the trial registry. The Japan approval and the pipeline catalysts check out. The FDA claim doesn't: the pivotal trial hasn't reported, and the company guides top-line data to late 2026 or early 2027. At ~$1.26B with no product revenue, the stock already prices in a lot of success ahead of that readout. *Price as of Oct 14, 2026 (intraday); financials as of June 30, 2026. Not financial advice.* --- ## Claim-by-claim | Claim in the post | Verdict | |---|---| | "Pre revenue with a pre revenue market cap" | Half true | | cSCC "market penetration estimated at $3.5B+" | No source found | | FDA approval "pretty much a done deal… early in the year at the latest" | Unsupported | | "Basically 100% ORR and a high CR % with no significant side effects" | Misleading | | Japan market authorization for H&N cancer | True | | "Negotiating pricing with the Japanese government as we speak" | Partly true | | Japan sales in 2026, early 2027 at the latest | No guidance supports it | | GBM: KOLs believe it "will become the standard of care" | No support found | | GBM results "this quarter" | Roughly matches guidance | | More catalysts (pancreas, prostate) | True | | "Fully commercial" in 2027 | Unsupported | ## Details **1. Pre-revenue market cap: half true.** Revenue is zero. The market cap is ~$1.26B (92.33M shares at ~$13.61), and the stock trades near the top of its 52-week range ($3.43–$15.79). That valuation already assumes a lot goes right. **2. "$3.5B+" cSCC market: no source found.** I couldn't find this figure in Alpha Tau's filings or releases. The pivotal trial also enrolls a narrow group: recurrent cSCC that has failed standard therapy, not a candidate for surgery or standard radiation, a single lesion up to 7 cm, and no nodal or distant spread. A first approval would be based on that population. **3. FDA "done deal": unsupported.** Alpha DaRT has Breakthrough Device Designation for recurrent cSCC, and Alpha Tau filed the first module of a modular PMA in January 2026. That module couldn't include pivotal results: the 88-patient ReSTART trial finished enrolling in May 2026, and the company guides top-line data to late 2026 or early 2027. ClinicalTrials.gov (last updated June 2026) lists estimated primary completion as April 2027. The clinical module needs that data, and FDA's review comes after. Breakthrough designation speeds up interaction with FDA; it doesn't guarantee approval. **4. "~100% ORR, no significant side effects": misleading.** No ReSTART efficacy or safety data has been released. The recent "100% ORR" headline comes from a different study: Alpha DaRT plus pembrolizumab in head-and-neck cancer, 9 evaluable patients (4 complete, 5 partial responses). Earlier skin-cancer results come from smaller pilot studies, and Alpha Tau's own risk factors note that preliminary data may not predict final results. Treating pilot-stage results as proof the pivotal will succeed is what makes the claim misleading. **5. Japan approval: true.** Japan's MHLW approved Alpha DaRT in February 2026 for unresectable locally advanced or locally recurrent head and neck cancer, the company's first approval outside Israel. HekaBio leads commercialization, and a post-marketing surveillance study is required. **6. Japan pricing: partly true.** In March 2026, management said reimbursement discussions with MHLW were starting, including the possibility of reimbursement during the post-marketing surveillance period. I couldn't find an announced reimbursement price as of mid-October. **7. Japan sales timing: no guidance supports it.** Alpha Tau hasn't guided Japan revenue. Management sized the approved population at a few hundred to a few thousand patients a year, so Japan sales would be modest even once they start. **8. GBM "standard of care": no support found.** REGAIN is a 10-patient U.S. feasibility trial. Interim data on the first 3 patients (cutoff May 3, 2026): 2 complete responses, 1 stable disease with a 30% tumor reduction, and one grade-3 serious adverse event that resolved with steroids. FDA cleared enrollment of the last 7 patients in June. Encouraging for three patients, but I couldn't find any KOL statement that it will become standard of care. **9. GBM results "this quarter": roughly matches guidance.** The company guides additional REGAIN data by around the end of 2026. That overlaps Q4 but isn't a firm date. **10. Other catalysts: true.** The IMPACT pancreatic pilot finished enrolling Aug 31, 2026, with initial data targeted for late 2026 or early 2027. A pooled analysis presented at ASCO 2026 reported 11.2-month median overall survival in metastatic pancreatic cancer after first-line chemo; the company compares that with roughly 4–6 months for second-line chemo in historical data (not a head-to-head trial). The first U.S. prostate pilot patient is expected in H2 2026, and Tolmar has U.S. commercialization rights for prostate. **11. "Fully commercial" in 2027: unsupported.** That requires FDA approval and a U.S. launch. Neither is assured, and the timing depends on data that isn't out yet. ## Financial snapshot - **Market cap:** ~$1.26B at ~$13.61 (Oct 14 intraday), 92.33M shares - **Cash, deposits and restricted deposits:** $104.8M at June 30, 2026, up from $76.9M at Dec 31, 2025 - **H1 2026 operating loss:** $27.1M. Net loss was $68.8M, mostly from $41.4M of net financial expense driven by remeasuring the warrant liability as the stock rose (non-cash). - **Runway:** no date given. At H1's operating-loss pace, cash covers about two years (rough proxy: operating loss includes non-cash stock comp and excludes capex for the planned U.S. plant). - **Dilution:** shares outstanding rose 4.9% in H1 (88.01M β†’ 92.33M). Public warrants (DRTSW) are outstanding, and exercises add shares. - **Tolmar deal (June 2026):** $20M equity at $11.99/share (25% premium to the 30-day VWAP), $15M toward a new U.S. production facility, up to $96.5M in development/regulatory milestones and up to $65M in commercial milestones for the first indication. Alpha Tau supplies product at 60% of net sales, subject to adjustments. - **Analysts:** 5, consensus Buy, average target $17.80 ## What to watch 1. **ReSTART top-line (late 2026 or early 2027).** Single-arm, open-label, 88 patients. Co-primary endpoints: confirmed objective response rate and duration of response 6 months after first response. Judge the readout against those, not against pilot numbers. 2. **REGAIN GBM update** (around end of 2026) 3. **IMPACT pancreatic initial data** (late 2026 or early 2027) 4. **Japan reimbursement listing** (no price announced yet) 5. **Q3 report** (estimated Nov 19, 2026) ## Bull vs. bear **Bull:** ReSTART hits both endpoints with clean safety, the PMA gets completed and approved, Japan reimbursement comes through, REGAIN and IMPACT hold up with more patients, and Tolmar milestones bring in non-dilutive cash. **Bear:** ReSTART response rates land below the pilot numbers, FDA asks for more data or longer follow-up, or good-but-not-perfect data still hits a stock trading near its 52-week high. Warrant exercises and any future raises add shares. ## Sources - [Q2 2026 results and corporate update (SEC 6-K, Aug 10, 2026)](https://www.sec.gov/Archives/edgar/data/1871321/000121390026087224/ea030079101ex99-3.htm) - [ReSTART pivotal trial on ClinicalTrials.gov (NCT05323253)](https://clinicaltrials.gov/study/NCT05323253) - [First PMA module submitted to FDA (Jan 2026)](https://www.biospace.com/press-releases/alpha-tau-submits-first-pre-market-approval-module-to-the-fda-for-alpha-dart-for-the-treatment-of-recurrent-cutaneous-squamous-cell-carcinoma-cscc) - [Japan marketing approval (Feb 2026)](https://www.alphatau.com/single-post/alpha-tau-medical-receives-japanese-marketing-approval-for-alpha-dart-in-unresectable-locally-advan) - [Management on Japan reimbursement and patient population (MarketBeat, Mar 2026)](https://www.marketbeat.com/instant-alerts/alpha-tau-medical-conference-japan-approval-rolling-fda-pma-and-big-2026-data-readouts-teased-2026-03-19/) - [REGAIN interim results and enrollment clearance (Jun 2026)](https://www.globenewswire.com/news-release/2026/06/11/3310444/0/en/Alpha-Tau-Receives-FDA-Clearance-to-Complete-Enrollment-in-REGAIN-Recurrent-Glioblastoma-Trial-and-Add-Two-U-S-Clinical-Sites-Early-Interim-Results-Showed-100-Local-Disease-Control.html) - [IMPACT enrollment complete (Aug 31, 2026)](https://www.globenewswire.com/news-release/2026/08/31/3353267/0/en/alpha-tau-completes-patient-enrollment-in-its-multicenter-impact-pancreatic-cancer-pilot-study-of-alpha-dart-following-strong-demand-and-multiple-expansions.html) - [Price, shares, analyst consensus (StockAnalysis)](https://stockanalysis.com/stocks/drts/)

Old and frail only for skin lesions, ok. But I wasn't talking about age. Look at that : [https://clinicaltrials.gov/study/NCT06910306](https://clinicaltrials.gov/study/NCT06910306) https://preview.redd.it/eg80ux482nth1.png?width=509&format=png&auto=webp&s=3b6afc8349aa64f0633c00a3a82a858767add06b

Mentions:#NCT

These are the main sources/studies i base my optimism off of: Initial Skin + Head and neck feasibility - [https://pubmed.ncbi.nlm.nih.gov/31759075/](https://pubmed.ncbi.nlm.nih.gov/31759075/) Another Skin feasibility where they upped the dosage - [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784) Pooled Skin + Head and neck combining the previous 2 trials and 2 trials for Israel - [https://pubmed.ncbi.nlm.nih.gov/39001374/](https://pubmed.ncbi.nlm.nih.gov/39001374/) Small Head and Neck study from Japan that got them approval in Japan - [https://pubmed.ncbi.nlm.nih.gov/39969694/](https://pubmed.ncbi.nlm.nih.gov/39969694/) Metastatic skin cancer + keytruda - [https://alphatau.com/wp-content/uploads/2026/07/Prof-Aron-Popovtzer-AHNS-Tuesday-July-21\_2026.pdf](https://alphatau.com/wp-content/uploads/2026/07/Prof-Aron-Popovtzer-AHNS-Tuesday-July-21_2026.pdf) Feasability/Safety pancreatic - [https://ascopubs.org/doi/10.1200/JCO.2026.44.2\_suppl.721](https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.721) Pooled pancreatic of previous study + Isreal study - [https://www.asco.org/abstracts-presentations/268234](https://www.asco.org/abstracts-presentations/268234) Very, very initial rGBM - [https://alphatau.com/wp-content/uploads/2026/05/AlphaTAU-GBM-Interim-05.11.26.pdf](https://alphatau.com/wp-content/uploads/2026/05/AlphaTAU-GBM-Interim-05.11.26.pdf) Meaningful upcoming (less than 6 months) results to see if the previous hold true: Restart Trial, pivotal trial to get approval for skin cancer, December/January - [https://clinicaltrials.gov/study/NCT05323253](https://clinicaltrials.gov/study/NCT05323253) Regain Trial, rGBM trial to start pivotal trial, more results expected December - [https://clinicaltrials.gov/study/NCT06910306](https://clinicaltrials.gov/study/NCT06910306) Impact Trial, pancreatic cancer trial to start pivotal trial, January/February - [https://clinicaltrials.gov/study/NCT06698458](https://clinicaltrials.gov/study/NCT06698458)

Mentions:#NCT

The [trial was not designed](https://clinicaltrials.gov/study/NCT06910306?term=DaRT,%20Alpha%20Tau&rank=6) to measure efficacy. It is a ten patient trial. You are correct about CR. I presume it is response measured by local radiographic control, which I assume to be some control (no growth, reduction of growth within limits) when measured using radiography.

Mentions:#NCT#CR
β€’r/wallstreetbetsSee Comment

The Moderna trial info is here. https://clinicaltrials.gov/study/NCT05933577?tab=results. look at the tab β€œno results posted”.

Mentions:#NCT
β€’r/wallstreetbetsSee Comment

Aren't they testing this treatment modality in like four or five other solid tumors right now? I'm trying to find more information about this trial, is it this one? https://clinicaltrials.gov/study/NCT05933577 They give completion dates of 2030+ but with these results I assume they're gonna end the trial early. That would make it, like, a two-year turnaround once they get to phase III, and I assume that will be faster now that the technology is proven.

Mentions:#NCT#III
β€’r/stocksSee Comment

Phase 1 unknown assets: LY4226695 (NCT07767487): Healthy, SC/IV LY4355756 (NCT07765498): Healthy, Tab/Cap \*!!!\*

Mentions:#NCT
β€’r/stocksSee Comment

Mazdutide: (NCT06817356): Phase 2, AUD, Primary Completion 8-2026 Macupatide +/- eloralintide: (NCT07765511): Phase 1, Obesity w/o T2D, Primary Completion 6-2027

Mentions:#NCT
β€’r/stocksSee Comment

FYI VA launches psilocybin trial for Veterans with treatment-resistant depression https://news.va.gov/press-room/va-launches-psilocybin-trial-for-veterans-with-treatment-resistant-depression/ https://clinicaltrials.gov/study/NCT07226232

Mentions:#NCT